Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Benjamin N, Greener"'
Publikováno v:
Immunological Medicine, Vol 46, Iss 1, Pp 58-60 (2023)
AbstractPrimary immunodeficiency (PI) patients may still experience persistent viral and bacterial respiratory infections with ongoing treatments. We report a challenging case of a PI patient who experienced recurrent viral respiratory infections des
Externí odkaz:
https://doaj.org/article/207c97fff3ed4af9b7ad56e70bb914e4
Publikováno v:
Immunological Medicine. 46:58-60
Primary immunodeficiency (PI) patients may still experience persistent viral and bacterial respiratory infections with ongoing treatments. We report a challenging case of a PI patient who experienced recurrent viral respiratory infections despite rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc49887e097a124951b3eddc5a976f55
https://doi.org/10.1080/25785826.2022.2151170
https://doi.org/10.1080/25785826.2022.2151170
Autor:
James Mond, Richard L. Wasserman, Daniel Garcia, Kaitlin M. Kestenberg, Benjamin N Greener, Adam S. Grossman, Adam Pinkert
Publikováno v:
Immunotherapy. 11:1423-1433
Humoral immunodeficiency patients require immunoglobulin replacement to prevent infection. Traditional intravenous immunoglobulin manufacturing methods have had the potential for containing impurities caused by physical, chemical and thermal stressor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14962292e1ad921580f3e7eb58444c7b
https://doi.org/10.2217/imt-2019-0157
https://doi.org/10.2217/imt-2019-0157
Autor:
Iñigo Narvaiza, Daniel C Linfesty, Benjamin N Greener, Yoshiyuki Hakata, David J Pintel, Eric Logue, Nathaniel R Landau, Matthew D Weitzman
Publikováno v:
PLoS Pathogens, Vol 5, Iss 5, p e1000439 (2009)
The APOBEC3 proteins form a multigene family of cytidine deaminases with inhibitory activity against viruses and retrotransposons. In contrast to APOBEC3G (A3G), APOBEC3A (A3A) has no effect on lentiviruses but dramatically inhibits replication of th
Externí odkaz:
https://doaj.org/article/c9be6e30441e4dc4b3b23d56c804e04b
Publikováno v:
Expert Review of Clinical Immunology
Introduction: Novel immune globulin (IG) products (RI-002, RI-001) have been designed to provide protection against respiratory syncytial virus (RSV) mediated respiratory illness while at the same time meeting the manufacturing requirements establish
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b39fe6b277186b7bfa8f2f3323cdda
http://europepmc.org/articles/PMC7103707
http://europepmc.org/articles/PMC7103707
Autor:
Richard L, Wasserman, Daniel, Garcia, Benjamin N, Greener, Kaitlin, Kestenberg, Adam, Pinkert, James, Mond, Adam, Grossman
Publikováno v:
Immunotherapy. 11(16)
Humoral immunodeficiency patients require immunoglobulin replacement to prevent infection. Traditional intravenous immunoglobulin manufacturing methods have had the potential for containing impurities caused by physical, chemical and thermal stressor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::24fdb523e83ab0fc9aa0c0a558e819d1
https://pubmed.ncbi.nlm.nih.gov/31596642
https://pubmed.ncbi.nlm.nih.gov/31596642
Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women
Autor:
Angela D. M. Kashuba, Benjamin N. Greener, Heather M.A. Prince, Julie B. Dumond, Craig Sykes, Kristine B. Patterson, Jessica L. Adams
Publikováno v:
Antiviral Therapy. 18:1005-1013
Background Antiretrovirals that achieve adequate concentrations in anatomical sites of transmission are of interest for HIV prevention. A Phase I open-label pharmacokinetic (PK) study was performed to describe first dose (PK1) and steady-state (PK2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::111fdd78ed615fcb4288a8f3abbab203
https://doi.org/10.3851/imp2665
https://doi.org/10.3851/imp2665
Autor:
Ryan D. Madanick, Angela D. M. Kashuba, Heather M.A. Prince, Benjamin N. Greener, Craig Sykes, Jessica L. Adams, Julie B. Dumond, Nicholas J. Shaheen, Kristine B. Patterson, Myron S. Cohen, Evan S. Dellon
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 64(1)
OBJECTIVES To describe first-dose and steady state pharmacokinetics (PKs) of dolutegravir (DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal fluid (RF) of healthy HIV-negative men. DESIGN A phase 1, open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a716699d95dc2fa4bcb56e99807b350
https://pubmed.ncbi.nlm.nih.gov/23945251
https://pubmed.ncbi.nlm.nih.gov/23945251
The purpose of this study is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir, and elvitegravir (both in phase III drug development).Data from January 2011 to April 2012 were eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244438a1ed815043b865d6af81df198c
Autor:
Daniel C. Linfesty, Iñigo Narvaiza, Matthew D. Weitzman, Nathaniel R. Landau, Benjamin N. Greener, David J. Pintel, Yoshiyuki Hakata, Eric C. Logue
Publikováno v:
PLoS Pathogens, Vol 5, Iss 5, p e1000439 (2009)
PLoS Pathogens
PLoS Pathogens
The APOBEC3 proteins form a multigene family of cytidine deaminases with inhibitory activity against viruses and retrotransposons. In contrast to APOBEC3G (A3G), APOBEC3A (A3A) has no effect on lentiviruses but dramatically inhibits replication of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab2fcc21c4ef11c6cd2be8329388a9d
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19461882/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19461882/?tool=EBI